NCT05245539 - Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

October 19, 2022

Study Completion Date

November 14, 2022

Conditions

Blood PressureSchizophrenia

Interventions

DRUG

CVL-231

CVL-231 is a brain penetrant mAChR activator that selectively binds to the M4 mAChR subtype while sparing other muscarinic receptor subtypes (M1, M2, M3, and M5). CVL-231 is being developed for treatment of psychosis in schizophrenia.

Trial Locations (10)

33016

Innovative Clinical Research, Inc - ClinEdge - PPDS, Miami

44720

Neuro-Behavioral Clinical Research, Inc., North Canton

60640

Uptown Research Institute LLC, Chicago

60712

Pillar Clinical Research LLC, Lincolnwood

72211

Woodland International Research Group LLC - ERG - PPDS, Little Rock

72712

Pillar Clinical Research LLC, Bentonville

75080

Pillar Clinical Research LLC, Richardson

78754

Community Clinical Research, Austin

90806

Collaborative NeuroScience Research, LLC - Torrance - Apex - PPDS, Long Beach

08053

Hassman Research Institute - Apex - PPDS, Marlton